Merit Financial Group
LRMR icon

Merit Financial Group’s Larimar Therapeutics LRMR Stock Holding History

Merit Financial Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,254
Closed -$31.3K – 2505
2026
Q2 		$31.3K Buy
+10,254
New +$40.7K ﹤0.01% 2318

Other funds holding LRMR

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return

Merit Financial Group's LRMR Position: Q3 2026 in Review

Merit Financial Group sold out of Larimar Therapeutics (LRMR) in Q3 2026, closing a stake of 10,254 shares — an estimated $31.3K sold.

Merit Financial Group first reported a position in LRMR in Q2 2026 and held it in 1 quarter. The position peaked at $31.3K in Q2 2026. 60 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • Merit Financial Group reported no remaining Larimar Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Merit Financial Group sold 10,254 Larimar Therapeutics shares in Q3 2026, an estimated $31.3K.
  • Merit Financial Group first reported a position in Larimar Therapeutics in Q2 2026 and held it in 1 quarter.
  • Merit Financial Group's Larimar Therapeutics position peaked at $31.3K in Q2 2026.
  • 60 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.